Compare · INCY vs ISPC
INCY vs ISPC
Side-by-side comparison of Incyte Corp. (INCY) and iSpecimen Inc. (ISPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and ISPC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $23.45B, about 6815.7x ISPC ($3.4M).
- Over the past year, INCY is up 69.3% and ISPC is down 94.5% - INCY leads by 163.8 points.
- INCY has been more active in the news (27 items in the past 4 weeks vs 3 for ISPC).
- INCY has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- Incyte Corp.
- iSpecimen Inc.
- Price
- $116.64-0.61%
- $2.29-1.08%
- Market cap
- $23.45B
- $3.4M
- 1M return
- +12.48%
- -11.05%
- 1Y return
- +69.29%
- -94.54%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 27
- 3
- Recent ratings
- 25
- 2
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest INCY
- Principal Accounting Officer Tray Thomas was granted 2,834 shares, increasing direct ownership by 15% to 21,699 units (SEC Form 4)
- CMO & Head of Late-Stage Dev. Stein Steven H sold $215,348 worth of shares (1,877 units at $114.73) and was granted 9,798 shares, increasing direct ownership by 34% to 30,916 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A was granted 5,916 shares, increasing direct ownership by 10% to 63,628 units (SEC Form 4)
- President, Global Head of R&D Cagnoni Pablo J was granted 13,403 shares, increasing direct ownership by 6% to 231,332 units (SEC Form 4)
- EVP, Head of U.S. Commercial Issa Mohamed Khairie sold $125,706 worth of shares (1,093 units at $115.01) and was granted 7,857 shares, increasing direct ownership by 10% to 71,797 units (SEC Form 4)
- EVP, Human Resources Basi Ramitpal K was granted 4,991 shares, increasing direct ownership by 77% to 11,497 units (SEC Form 4)
- EVP, Chief Strategy Officer Gardner David H was granted 7,395 shares, increasing direct ownership by 78% to 16,824 units (SEC Form 4)
- EVP & General Counsel Hoffman Richard A. was granted 7,395 shares, increasing direct ownership by 78% to 16,861 units (SEC Form 4)
- Chief Executive Officer Meury William was granted 26,807 shares, increasing direct ownership by 17% to 183,129 units (SEC Form 4)
- Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Latest ISPC
- Amendment: SEC Form S-1/A filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form S-1/A filed by iSpecimen Inc.
- SEC Form S-1 filed by iSpecimen Inc.
- SEC Form EFFECT filed by iSpecimen Inc.
- SEC Form S-3 filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by iSpecimen Inc.
- SEC Form D filed by iSpecimen Inc.